nodes	percent_of_prediction	percent_of_DWPC	metapath
Galantamine—CHRNA5—prostate gland—urinary bladder cancer	0.0254	0.105	CbGeAlD
Galantamine—CHRNG—prostate gland—urinary bladder cancer	0.0181	0.0753	CbGeAlD
Galantamine—CHRNG—seminal vesicle—urinary bladder cancer	0.0153	0.0637	CbGeAlD
Galantamine—CHRNA5—vagina—urinary bladder cancer	0.0125	0.0521	CbGeAlD
Galantamine—Ethylmorphine—POR—urinary bladder cancer	0.0125	0.46	CrCbGaD
Galantamine—CHRNA1—prostate gland—urinary bladder cancer	0.012	0.0499	CbGeAlD
Galantamine—CHRNB2—prostate gland—urinary bladder cancer	0.011	0.0459	CbGeAlD
Galantamine—CHRNA3—prostate gland—urinary bladder cancer	0.0107	0.0445	CbGeAlD
Galantamine—BCHE—Cisplatin—urinary bladder cancer	0.0107	0.51	CbGbCtD
Galantamine—CHRNA2—prostate gland—urinary bladder cancer	0.00996	0.0414	CbGeAlD
Galantamine—CHRNB1—prostate gland—urinary bladder cancer	0.00927	0.0385	CbGeAlD
Galantamine—CHRNA5—lymph node—urinary bladder cancer	0.0081	0.0337	CbGeAlD
Galantamine—Codeine—UGT2B7—urinary bladder cancer	0.0081	0.298	CrCbGaD
Galantamine—ACHE—prostate gland—urinary bladder cancer	0.00804	0.0334	CbGeAlD
Galantamine—CHRNB2—smooth muscle tissue—urinary bladder cancer	0.00782	0.0325	CbGeAlD
Galantamine—CHRNA10—vagina—urinary bladder cancer	0.00759	0.0315	CbGeAlD
Galantamine—CYP3A4—urine—urinary bladder cancer	0.00741	0.0308	CbGeAlD
Galantamine—CHRNB2—urethra—urinary bladder cancer	0.0074	0.0307	CbGeAlD
Galantamine—CYP2D6—urine—urinary bladder cancer	0.00729	0.0303	CbGeAlD
Galantamine—Morphine—UGT2B7—urinary bladder cancer	0.00656	0.242	CrCbGaD
Galantamine—CYP3A4—Thiotepa—urinary bladder cancer	0.00589	0.281	CbGbCtD
Galantamine—CHRNB2—vagina—urinary bladder cancer	0.00545	0.0227	CbGeAlD
Galantamine—CHRNA10—lymph node—urinary bladder cancer	0.00491	0.0204	CbGeAlD
Galantamine—CHRNA7—renal system—urinary bladder cancer	0.00477	0.0198	CbGeAlD
Galantamine—CHRFAM7A—female reproductive system—urinary bladder cancer	0.00473	0.0197	CbGeAlD
Galantamine—CHRNB1—vagina—urinary bladder cancer	0.00458	0.019	CbGeAlD
Galantamine—BCHE—prostate gland—urinary bladder cancer	0.00395	0.0164	CbGeAlD
Galantamine—CHRNA7—female reproductive system—urinary bladder cancer	0.00382	0.0159	CbGeAlD
Galantamine—CHRNB2—lymph node—urinary bladder cancer	0.00353	0.0147	CbGeAlD
Galantamine—CHRNA3—lymph node—urinary bladder cancer	0.00342	0.0142	CbGeAlD
Galantamine—BCHE—seminal vesicle—urinary bladder cancer	0.00334	0.0139	CbGeAlD
Galantamine—CHRNB1—lymph node—urinary bladder cancer	0.00296	0.0123	CbGeAlD
Galantamine—BCHE—smooth muscle tissue—urinary bladder cancer	0.0028	0.0116	CbGeAlD
Galantamine—ACHE—lymph node—urinary bladder cancer	0.00257	0.0107	CbGeAlD
Galantamine—BCHE—female reproductive system—urinary bladder cancer	0.00216	0.00896	CbGeAlD
Galantamine—BCHE—vagina—urinary bladder cancer	0.00195	0.0081	CbGeAlD
Galantamine—CYP3A4—renal system—urinary bladder cancer	0.00181	0.00753	CbGeAlD
Galantamine—CYP2D6—renal system—urinary bladder cancer	0.00178	0.00741	CbGeAlD
Galantamine—CYP2D6—Doxorubicin—urinary bladder cancer	0.00171	0.0817	CbGbCtD
Galantamine—CYP3A4—Etoposide—urinary bladder cancer	0.0016	0.0761	CbGbCtD
Galantamine—CYP3A4—female reproductive system—urinary bladder cancer	0.00145	0.00603	CbGeAlD
Galantamine—CYP2D6—female reproductive system—urinary bladder cancer	0.00143	0.00593	CbGeAlD
Galantamine—BCHE—lymph node—urinary bladder cancer	0.00126	0.00524	CbGeAlD
Galantamine—CYP3A4—Doxorubicin—urinary bladder cancer	0.00109	0.0519	CbGbCtD
Galantamine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000561	0.000791	CcSEcCtD
Galantamine—Asthenia—Gemcitabine—urinary bladder cancer	0.00056	0.000789	CcSEcCtD
Galantamine—Haematuria—Epirubicin—urinary bladder cancer	0.000558	0.000787	CcSEcCtD
Galantamine—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000554	0.000781	CcSEcCtD
Galantamine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000554	0.00078	CcSEcCtD
Galantamine—Epistaxis—Epirubicin—urinary bladder cancer	0.000552	0.000778	CcSEcCtD
Galantamine—Nausea—Thiotepa—urinary bladder cancer	0.000551	0.000776	CcSEcCtD
Galantamine—Urethral disorder—Methotrexate—urinary bladder cancer	0.00055	0.000776	CcSEcCtD
Galantamine—Weight decreased—Doxorubicin—urinary bladder cancer	0.000549	0.000775	CcSEcCtD
Galantamine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000549	0.000773	CcSEcCtD
Galantamine—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000548	0.000772	CcSEcCtD
Galantamine—Pneumonia—Doxorubicin—urinary bladder cancer	0.000545	0.000768	CcSEcCtD
Galantamine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000545	0.000768	CcSEcCtD
Galantamine—Visual impairment—Methotrexate—urinary bladder cancer	0.000541	0.000763	CcSEcCtD
Galantamine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000536	0.000755	CcSEcCtD
Galantamine—Bradycardia—Epirubicin—urinary bladder cancer	0.000535	0.000754	CcSEcCtD
Galantamine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000534	0.000752	CcSEcCtD
Galantamine—Renal failure—Doxorubicin—urinary bladder cancer	0.000532	0.00075	CcSEcCtD
Galantamine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000531	0.000748	CcSEcCtD
Galantamine—Haemoglobin—Epirubicin—urinary bladder cancer	0.000528	0.000744	CcSEcCtD
Galantamine—Rhinitis—Epirubicin—urinary bladder cancer	0.000527	0.000742	CcSEcCtD
Galantamine—Abdominal pain—Etoposide—urinary bladder cancer	0.000526	0.000742	CcSEcCtD
Galantamine—Body temperature increased—Etoposide—urinary bladder cancer	0.000526	0.000742	CcSEcCtD
Galantamine—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000526	0.000742	CcSEcCtD
Galantamine—Hepatitis—Epirubicin—urinary bladder cancer	0.000525	0.000741	CcSEcCtD
Galantamine—Haemorrhage—Epirubicin—urinary bladder cancer	0.000525	0.000741	CcSEcCtD
Galantamine—Eye disorder—Methotrexate—urinary bladder cancer	0.000525	0.00074	CcSEcCtD
Galantamine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000525	0.000739	CcSEcCtD
Galantamine—Tinnitus—Methotrexate—urinary bladder cancer	0.000523	0.000738	CcSEcCtD
Galantamine—Asthenia—Cisplatin—urinary bladder cancer	0.000522	0.000735	CcSEcCtD
Galantamine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000521	0.000734	CcSEcCtD
Galantamine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000519	0.000731	CcSEcCtD
Galantamine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000518	0.00073	CcSEcCtD
Galantamine—Haematuria—Doxorubicin—urinary bladder cancer	0.000516	0.000728	CcSEcCtD
Galantamine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000516	0.000728	CcSEcCtD
Galantamine—Urethral disorder—Epirubicin—urinary bladder cancer	0.000515	0.000726	CcSEcCtD
Galantamine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000512	0.000722	CcSEcCtD
Galantamine—Epistaxis—Doxorubicin—urinary bladder cancer	0.000511	0.00072	CcSEcCtD
Galantamine—Angiopathy—Methotrexate—urinary bladder cancer	0.000509	0.000718	CcSEcCtD
Galantamine—Immune system disorder—Methotrexate—urinary bladder cancer	0.000507	0.000715	CcSEcCtD
Galantamine—Dizziness—Fluorouracil—urinary bladder cancer	0.000507	0.000715	CcSEcCtD
Galantamine—Visual impairment—Epirubicin—urinary bladder cancer	0.000506	0.000714	CcSEcCtD
Galantamine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000497	0.000701	CcSEcCtD
Galantamine—Vomiting—Gemcitabine—urinary bladder cancer	0.000496	0.000699	CcSEcCtD
Galantamine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000495	0.000698	CcSEcCtD
Galantamine—Mental disorder—Methotrexate—urinary bladder cancer	0.000492	0.000693	CcSEcCtD
Galantamine—Rash—Gemcitabine—urinary bladder cancer	0.000492	0.000693	CcSEcCtD
Galantamine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000491	0.000692	CcSEcCtD
Galantamine—Eye disorder—Epirubicin—urinary bladder cancer	0.000491	0.000692	CcSEcCtD
Galantamine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000491	0.000692	CcSEcCtD
Galantamine—Tinnitus—Epirubicin—urinary bladder cancer	0.00049	0.00069	CcSEcCtD
Galantamine—Malnutrition—Methotrexate—urinary bladder cancer	0.000489	0.000689	CcSEcCtD
Galantamine—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000489	0.000689	CcSEcCtD
Galantamine—Headache—Gemcitabine—urinary bladder cancer	0.000489	0.000689	CcSEcCtD
Galantamine—Flushing—Epirubicin—urinary bladder cancer	0.000488	0.000687	CcSEcCtD
Galantamine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000488	0.000687	CcSEcCtD
Galantamine—Vomiting—Fluorouracil—urinary bladder cancer	0.000488	0.000687	CcSEcCtD
Galantamine—Rhinitis—Doxorubicin—urinary bladder cancer	0.000487	0.000687	CcSEcCtD
Galantamine—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000486	0.000685	CcSEcCtD
Galantamine—Hepatitis—Doxorubicin—urinary bladder cancer	0.000486	0.000685	CcSEcCtD
Galantamine—Rash—Fluorouracil—urinary bladder cancer	0.000483	0.000681	CcSEcCtD
Galantamine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000483	0.000681	CcSEcCtD
Galantamine—Headache—Fluorouracil—urinary bladder cancer	0.00048	0.000677	CcSEcCtD
Galantamine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.00048	0.000677	CcSEcCtD
Galantamine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000479	0.000675	CcSEcCtD
Galantamine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000479	0.000675	CcSEcCtD
Galantamine—Asthenia—Etoposide—urinary bladder cancer	0.000478	0.000673	CcSEcCtD
Galantamine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000478	0.000673	CcSEcCtD
Galantamine—Angiopathy—Epirubicin—urinary bladder cancer	0.000477	0.000672	CcSEcCtD
Galantamine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000477	0.000672	CcSEcCtD
Galantamine—Immune system disorder—Epirubicin—urinary bladder cancer	0.000475	0.000669	CcSEcCtD
Galantamine—Back pain—Methotrexate—urinary bladder cancer	0.000473	0.000666	CcSEcCtD
Galantamine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000469	0.000662	CcSEcCtD
Galantamine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000468	0.00066	CcSEcCtD
Galantamine—Nausea—Gemcitabine—urinary bladder cancer	0.000463	0.000653	CcSEcCtD
Galantamine—Vomiting—Cisplatin—urinary bladder cancer	0.000462	0.000651	CcSEcCtD
Galantamine—Vision blurred—Methotrexate—urinary bladder cancer	0.000461	0.000649	CcSEcCtD
Galantamine—Mental disorder—Epirubicin—urinary bladder cancer	0.00046	0.000649	CcSEcCtD
Galantamine—Rash—Cisplatin—urinary bladder cancer	0.000458	0.000646	CcSEcCtD
Galantamine—Dermatitis—Cisplatin—urinary bladder cancer	0.000458	0.000645	CcSEcCtD
Galantamine—Malnutrition—Epirubicin—urinary bladder cancer	0.000457	0.000645	CcSEcCtD
Galantamine—Diarrhoea—Etoposide—urinary bladder cancer	0.000456	0.000642	CcSEcCtD
Galantamine—Nausea—Fluorouracil—urinary bladder cancer	0.000455	0.000642	CcSEcCtD
Galantamine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000454	0.00064	CcSEcCtD
Galantamine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000453	0.000639	CcSEcCtD
Galantamine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000453	0.000639	CcSEcCtD
Galantamine—Anaemia—Methotrexate—urinary bladder cancer	0.000452	0.000637	CcSEcCtD
Galantamine—Flushing—Doxorubicin—urinary bladder cancer	0.000451	0.000636	CcSEcCtD
Galantamine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000451	0.000636	CcSEcCtD
Galantamine—Flatulence—Epirubicin—urinary bladder cancer	0.000451	0.000635	CcSEcCtD
Galantamine—Tension—Epirubicin—urinary bladder cancer	0.000449	0.000633	CcSEcCtD
Galantamine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000448	0.000631	CcSEcCtD
Galantamine—Nervousness—Epirubicin—urinary bladder cancer	0.000444	0.000626	CcSEcCtD
Galantamine—Back pain—Epirubicin—urinary bladder cancer	0.000442	0.000624	CcSEcCtD
Galantamine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000441	0.000622	CcSEcCtD
Galantamine—Malaise—Methotrexate—urinary bladder cancer	0.000441	0.000621	CcSEcCtD
Galantamine—Dizziness—Etoposide—urinary bladder cancer	0.00044	0.000621	CcSEcCtD
Galantamine—Muscle spasms—Epirubicin—urinary bladder cancer	0.00044	0.00062	CcSEcCtD
Galantamine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000439	0.000619	CcSEcCtD
Galantamine—Vertigo—Methotrexate—urinary bladder cancer	0.000439	0.000619	CcSEcCtD
Galantamine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000434	0.000612	CcSEcCtD
Galantamine—Nausea—Cisplatin—urinary bladder cancer	0.000432	0.000609	CcSEcCtD
Galantamine—Vision blurred—Epirubicin—urinary bladder cancer	0.000431	0.000608	CcSEcCtD
Galantamine—Cough—Methotrexate—urinary bladder cancer	0.000426	0.000601	CcSEcCtD
Galantamine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000426	0.0006	CcSEcCtD
Galantamine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000424	0.000598	CcSEcCtD
Galantamine—Convulsion—Methotrexate—urinary bladder cancer	0.000423	0.000597	CcSEcCtD
Galantamine—Vomiting—Etoposide—urinary bladder cancer	0.000423	0.000597	CcSEcCtD
Galantamine—Malnutrition—Doxorubicin—urinary bladder cancer	0.000423	0.000596	CcSEcCtD
Galantamine—Anaemia—Epirubicin—urinary bladder cancer	0.000423	0.000596	CcSEcCtD
Galantamine—Agitation—Epirubicin—urinary bladder cancer	0.00042	0.000592	CcSEcCtD
Galantamine—Rash—Etoposide—urinary bladder cancer	0.00042	0.000592	CcSEcCtD
Galantamine—Dermatitis—Etoposide—urinary bladder cancer	0.000419	0.000591	CcSEcCtD
Galantamine—Headache—Etoposide—urinary bladder cancer	0.000417	0.000588	CcSEcCtD
Galantamine—Flatulence—Doxorubicin—urinary bladder cancer	0.000417	0.000588	CcSEcCtD
Galantamine—Arthralgia—Methotrexate—urinary bladder cancer	0.000416	0.000586	CcSEcCtD
Galantamine—Myalgia—Methotrexate—urinary bladder cancer	0.000416	0.000586	CcSEcCtD
Galantamine—Chest pain—Methotrexate—urinary bladder cancer	0.000416	0.000586	CcSEcCtD
Galantamine—Tension—Doxorubicin—urinary bladder cancer	0.000415	0.000585	CcSEcCtD
Galantamine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000414	0.000584	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000413	0.000582	CcSEcCtD
Galantamine—Malaise—Epirubicin—urinary bladder cancer	0.000412	0.000581	CcSEcCtD
Galantamine—Discomfort—Methotrexate—urinary bladder cancer	0.000411	0.000579	CcSEcCtD
Galantamine—Nervousness—Doxorubicin—urinary bladder cancer	0.000411	0.000579	CcSEcCtD
Galantamine—Vertigo—Epirubicin—urinary bladder cancer	0.000411	0.000579	CcSEcCtD
Galantamine—Syncope—Epirubicin—urinary bladder cancer	0.00041	0.000578	CcSEcCtD
Galantamine—Back pain—Doxorubicin—urinary bladder cancer	0.000409	0.000577	CcSEcCtD
Galantamine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000407	0.000573	CcSEcCtD
Galantamine—Palpitations—Epirubicin—urinary bladder cancer	0.000404	0.00057	CcSEcCtD
Galantamine—Confusional state—Methotrexate—urinary bladder cancer	0.000402	0.000567	CcSEcCtD
Galantamine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000402	0.000567	CcSEcCtD
Galantamine—Cough—Epirubicin—urinary bladder cancer	0.000399	0.000563	CcSEcCtD
Galantamine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000399	0.000562	CcSEcCtD
Galantamine—Convulsion—Epirubicin—urinary bladder cancer	0.000396	0.000559	CcSEcCtD
Galantamine—Nausea—Etoposide—urinary bladder cancer	0.000396	0.000558	CcSEcCtD
Galantamine—Hypertension—Epirubicin—urinary bladder cancer	0.000395	0.000557	CcSEcCtD
Galantamine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000393	0.000553	CcSEcCtD
Galantamine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000391	0.000551	CcSEcCtD
Galantamine—Anaemia—Doxorubicin—urinary bladder cancer	0.000391	0.000551	CcSEcCtD
Galantamine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000391	0.00055	CcSEcCtD
Galantamine—Chest pain—Epirubicin—urinary bladder cancer	0.000389	0.000549	CcSEcCtD
Galantamine—Arthralgia—Epirubicin—urinary bladder cancer	0.000389	0.000549	CcSEcCtD
Galantamine—Myalgia—Epirubicin—urinary bladder cancer	0.000389	0.000549	CcSEcCtD
Galantamine—Agitation—Doxorubicin—urinary bladder cancer	0.000389	0.000548	CcSEcCtD
Galantamine—Anxiety—Epirubicin—urinary bladder cancer	0.000388	0.000547	CcSEcCtD
Galantamine—Skin disorder—Methotrexate—urinary bladder cancer	0.000387	0.000546	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000387	0.000545	CcSEcCtD
Galantamine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000386	0.000544	CcSEcCtD
Galantamine—Discomfort—Epirubicin—urinary bladder cancer	0.000385	0.000542	CcSEcCtD
Galantamine—Malaise—Doxorubicin—urinary bladder cancer	0.000382	0.000538	CcSEcCtD
Galantamine—Dry mouth—Epirubicin—urinary bladder cancer	0.000381	0.000537	CcSEcCtD
Galantamine—Vertigo—Doxorubicin—urinary bladder cancer	0.00038	0.000536	CcSEcCtD
Galantamine—Anorexia—Methotrexate—urinary bladder cancer	0.00038	0.000536	CcSEcCtD
Galantamine—Syncope—Doxorubicin—urinary bladder cancer	0.00038	0.000535	CcSEcCtD
Galantamine—Confusional state—Epirubicin—urinary bladder cancer	0.000376	0.000531	CcSEcCtD
Galantamine—Palpitations—Doxorubicin—urinary bladder cancer	0.000374	0.000527	CcSEcCtD
Galantamine—Hypotension—Methotrexate—urinary bladder cancer	0.000373	0.000525	CcSEcCtD
Galantamine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000372	0.000524	CcSEcCtD
Galantamine—Cough—Doxorubicin—urinary bladder cancer	0.000369	0.000521	CcSEcCtD
Galantamine—Shock—Epirubicin—urinary bladder cancer	0.000367	0.000518	CcSEcCtD
Galantamine—Convulsion—Doxorubicin—urinary bladder cancer	0.000367	0.000517	CcSEcCtD
Galantamine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000366	0.000516	CcSEcCtD
Galantamine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000365	0.000515	CcSEcCtD
Galantamine—Hypertension—Doxorubicin—urinary bladder cancer	0.000365	0.000515	CcSEcCtD
Galantamine—Tachycardia—Epirubicin—urinary bladder cancer	0.000364	0.000513	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000363	0.000512	CcSEcCtD
Galantamine—Skin disorder—Epirubicin—urinary bladder cancer	0.000363	0.000511	CcSEcCtD
Galantamine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000361	0.000509	CcSEcCtD
Galantamine—Insomnia—Methotrexate—urinary bladder cancer	0.000361	0.000508	CcSEcCtD
Galantamine—Myalgia—Doxorubicin—urinary bladder cancer	0.00036	0.000508	CcSEcCtD
Galantamine—Arthralgia—Doxorubicin—urinary bladder cancer	0.00036	0.000508	CcSEcCtD
Galantamine—Chest pain—Doxorubicin—urinary bladder cancer	0.00036	0.000508	CcSEcCtD
Galantamine—Anxiety—Doxorubicin—urinary bladder cancer	0.000359	0.000506	CcSEcCtD
Galantamine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000358	0.000505	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000358	0.000504	CcSEcCtD
Galantamine—Discomfort—Doxorubicin—urinary bladder cancer	0.000356	0.000502	CcSEcCtD
Galantamine—Anorexia—Epirubicin—urinary bladder cancer	0.000356	0.000502	CcSEcCtD
Galantamine—Somnolence—Methotrexate—urinary bladder cancer	0.000355	0.0005	CcSEcCtD
Galantamine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000352	0.000497	CcSEcCtD
Galantamine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000351	0.000495	CcSEcCtD
Galantamine—Hypotension—Epirubicin—urinary bladder cancer	0.000349	0.000492	CcSEcCtD
Galantamine—Confusional state—Doxorubicin—urinary bladder cancer	0.000348	0.000491	CcSEcCtD
Galantamine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000347	0.000489	CcSEcCtD
Galantamine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000344	0.000485	CcSEcCtD
Galantamine—Fatigue—Methotrexate—urinary bladder cancer	0.000344	0.000485	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00034	0.000479	CcSEcCtD
Galantamine—Shock—Doxorubicin—urinary bladder cancer	0.00034	0.000479	CcSEcCtD
Galantamine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000339	0.000477	CcSEcCtD
Galantamine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000338	0.000477	CcSEcCtD
Galantamine—Insomnia—Epirubicin—urinary bladder cancer	0.000338	0.000476	CcSEcCtD
Galantamine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000337	0.000475	CcSEcCtD
Galantamine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000335	0.000473	CcSEcCtD
Galantamine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000335	0.000472	CcSEcCtD
Galantamine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000334	0.000471	CcSEcCtD
Galantamine—Somnolence—Epirubicin—urinary bladder cancer	0.000332	0.000468	CcSEcCtD
Galantamine—Anorexia—Doxorubicin—urinary bladder cancer	0.000329	0.000464	CcSEcCtD
Galantamine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000329	0.000463	CcSEcCtD
Galantamine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000329	0.000463	CcSEcCtD
Galantamine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000326	0.00046	CcSEcCtD
Galantamine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000324	0.000457	CcSEcCtD
Galantamine—Hypotension—Doxorubicin—urinary bladder cancer	0.000323	0.000455	CcSEcCtD
Galantamine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000322	0.000454	CcSEcCtD
Galantamine—Fatigue—Epirubicin—urinary bladder cancer	0.000322	0.000454	CcSEcCtD
Galantamine—Constipation—Epirubicin—urinary bladder cancer	0.000319	0.00045	CcSEcCtD
Galantamine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000315	0.000444	CcSEcCtD
Galantamine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000315	0.000444	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000315	0.000444	CcSEcCtD
Galantamine—Insomnia—Doxorubicin—urinary bladder cancer	0.000312	0.00044	CcSEcCtD
Galantamine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00031	0.000437	CcSEcCtD
Galantamine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000308	0.000434	CcSEcCtD
Galantamine—Somnolence—Doxorubicin—urinary bladder cancer	0.000307	0.000433	CcSEcCtD
Galantamine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000305	0.00043	CcSEcCtD
Galantamine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000304	0.000429	CcSEcCtD
Galantamine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.0003	0.000423	CcSEcCtD
Galantamine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000298	0.00042	CcSEcCtD
Galantamine—Fatigue—Doxorubicin—urinary bladder cancer	0.000298	0.00042	CcSEcCtD
Galantamine—Constipation—Doxorubicin—urinary bladder cancer	0.000295	0.000416	CcSEcCtD
Galantamine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000295	0.000416	CcSEcCtD
Galantamine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000295	0.000416	CcSEcCtD
Galantamine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000294	0.000414	CcSEcCtD
Galantamine—Asthenia—Methotrexate—urinary bladder cancer	0.000286	0.000403	CcSEcCtD
Galantamine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000285	0.000401	CcSEcCtD
Galantamine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000282	0.000398	CcSEcCtD
Galantamine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000275	0.000388	CcSEcCtD
Galantamine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000273	0.000385	CcSEcCtD
Galantamine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000273	0.000385	CcSEcCtD
Galantamine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000273	0.000385	CcSEcCtD
Galantamine—Asthenia—Epirubicin—urinary bladder cancer	0.000268	0.000377	CcSEcCtD
Galantamine—Dizziness—Methotrexate—urinary bladder cancer	0.000264	0.000372	CcSEcCtD
Galantamine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000255	0.00036	CcSEcCtD
Galantamine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000254	0.000359	CcSEcCtD
Galantamine—Vomiting—Methotrexate—urinary bladder cancer	0.000254	0.000357	CcSEcCtD
Galantamine—Rash—Methotrexate—urinary bladder cancer	0.000251	0.000354	CcSEcCtD
Galantamine—Dermatitis—Methotrexate—urinary bladder cancer	0.000251	0.000354	CcSEcCtD
Galantamine—Headache—Methotrexate—urinary bladder cancer	0.00025	0.000352	CcSEcCtD
Galantamine—Asthenia—Doxorubicin—urinary bladder cancer	0.000248	0.000349	CcSEcCtD
Galantamine—Dizziness—Epirubicin—urinary bladder cancer	0.000247	0.000348	CcSEcCtD
Galantamine—Vomiting—Epirubicin—urinary bladder cancer	0.000237	0.000335	CcSEcCtD
Galantamine—Nausea—Methotrexate—urinary bladder cancer	0.000237	0.000334	CcSEcCtD
Galantamine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000236	0.000333	CcSEcCtD
Galantamine—Rash—Epirubicin—urinary bladder cancer	0.000235	0.000332	CcSEcCtD
Galantamine—Dermatitis—Epirubicin—urinary bladder cancer	0.000235	0.000331	CcSEcCtD
Galantamine—Headache—Epirubicin—urinary bladder cancer	0.000234	0.00033	CcSEcCtD
Galantamine—Dizziness—Doxorubicin—urinary bladder cancer	0.000228	0.000322	CcSEcCtD
Galantamine—Nausea—Epirubicin—urinary bladder cancer	0.000222	0.000313	CcSEcCtD
Galantamine—Vomiting—Doxorubicin—urinary bladder cancer	0.00022	0.00031	CcSEcCtD
Galantamine—Rash—Doxorubicin—urinary bladder cancer	0.000218	0.000307	CcSEcCtD
Galantamine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000218	0.000307	CcSEcCtD
Galantamine—Headache—Doxorubicin—urinary bladder cancer	0.000216	0.000305	CcSEcCtD
Galantamine—Nausea—Doxorubicin—urinary bladder cancer	0.000205	0.000289	CcSEcCtD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	8.1e-06	0.00465	CbGpPWpGaD
Galantamine—ACHE—Monoamine Transport—TNF—urinary bladder cancer	8.03e-06	0.0046	CbGpPWpGaD
Galantamine—CHRNA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	7.84e-06	0.0045	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	7.61e-06	0.00437	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	7.51e-06	0.00431	CbGpPWpGaD
Galantamine—CHRNG—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	7.48e-06	0.00429	CbGpPWpGaD
Galantamine—CHRNA9—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	7.11e-06	0.00408	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—CXCL8—urinary bladder cancer	7.07e-06	0.00405	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	7.03e-06	0.00403	CbGpPWpGaD
Galantamine—CHRNE—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	7.03e-06	0.00403	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	7.01e-06	0.00402	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	6.86e-06	0.00393	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	6.76e-06	0.00388	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—CCND1—urinary bladder cancer	6.58e-06	0.00378	CbGpPWpGaD
Galantamine—ACHE—Peptide hormone metabolism—IGF1—urinary bladder cancer	6.56e-06	0.00376	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	6.54e-06	0.00375	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	6.43e-06	0.00369	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	6.42e-06	0.00368	CbGpPWpGaD
Galantamine—CHRNB3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	6.21e-06	0.00356	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—EP300—urinary bladder cancer	6.06e-06	0.00348	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—PTEN—urinary bladder cancer	6e-06	0.00344	CbGpPWpGaD
Galantamine—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	5.94e-06	0.00341	CbGpPWpGaD
Galantamine—CHRNA5—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	5.89e-06	0.00338	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—IGF1—urinary bladder cancer	5.85e-06	0.00336	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	5.74e-06	0.00329	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	5.73e-06	0.00329	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	5.73e-06	0.00328	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—EP300—urinary bladder cancer	5.72e-06	0.00328	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	5.69e-06	0.00326	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	5.66e-06	0.00325	CbGpPWpGaD
Galantamine—CHRNG—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	5.62e-06	0.00322	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	5.58e-06	0.0032	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	5.52e-06	0.00316	CbGpPWpGaD
Galantamine—CHRNA9—Neuronal System—HRAS—urinary bladder cancer	5.45e-06	0.00312	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	5.44e-06	0.00312	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	5.44e-06	0.00312	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	5.37e-06	0.00308	CbGpPWpGaD
Galantamine—CHRNE—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	5.28e-06	0.00303	CbGpPWpGaD
Galantamine—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	5.23e-06	0.003	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	5.2e-06	0.00298	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	5.11e-06	0.00293	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	4.98e-06	0.00286	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	4.91e-06	0.00282	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	4.79e-06	0.00275	CbGpPWpGaD
Galantamine—CHRNB3—Neuronal System—HRAS—urinary bladder cancer	4.76e-06	0.00273	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—CDX2—urinary bladder cancer	4.67e-06	0.00268	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	4.56e-06	0.00262	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	4.55e-06	0.00261	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	4.53e-06	0.0026	CbGpPWpGaD
Galantamine—CHRNA5—Neuronal System—HRAS—urinary bladder cancer	4.51e-06	0.00259	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	4.5e-06	0.00258	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	4.48e-06	0.00257	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	4.48e-06	0.00257	CbGpPWpGaD
Galantamine—CHRNA6—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	4.46e-06	0.00256	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	4.42e-06	0.00254	CbGpPWpGaD
Galantamine—CHRNG—Neuronal System—HRAS—urinary bladder cancer	4.31e-06	0.00247	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—CDX2—urinary bladder cancer	4.16e-06	0.00239	CbGpPWpGaD
Galantamine—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	4.16e-06	0.00239	CbGpPWpGaD
Galantamine—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	4.12e-06	0.00236	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—TP53—urinary bladder cancer	4.09e-06	0.00235	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—HRAS—urinary bladder cancer	4.05e-06	0.00232	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	4e-06	0.00229	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	3.98e-06	0.00229	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	3.97e-06	0.00228	CbGpPWpGaD
Galantamine—CHRNB2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	3.93e-06	0.00225	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	3.9e-06	0.00224	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	3.89e-06	0.00223	CbGpPWpGaD
Galantamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	3.86e-06	0.00221	CbGpPWpGaD
Galantamine—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	3.77e-06	0.00216	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSTZ1—urinary bladder cancer	3.66e-06	0.0021	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	3.65e-06	0.00209	CbGpPWpGaD
Galantamine—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	3.57e-06	0.00205	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	3.54e-06	0.00203	CbGpPWpGaD
Galantamine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	3.54e-06	0.00203	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	3.48e-06	0.00199	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSTO2—urinary bladder cancer	3.47e-06	0.00199	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NAT1—urinary bladder cancer	3.47e-06	0.00199	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.43e-06	0.00197	CbGpPWpGaD
Galantamine—CHRNA6—Neuronal System—HRAS—urinary bladder cancer	3.42e-06	0.00196	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.41e-06	0.00196	CbGpPWpGaD
Galantamine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	3.36e-06	0.00193	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSTZ1—urinary bladder cancer	3.27e-06	0.00187	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—PTEN—urinary bladder cancer	3.22e-06	0.00185	CbGpPWpGaD
Galantamine—ACHE—Metabolism—UGT2B7—urinary bladder cancer	3.17e-06	0.00182	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	3.17e-06	0.00182	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	3.13e-06	0.00179	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSTO2—urinary bladder cancer	3.1e-06	0.00178	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NAT1—urinary bladder cancer	3.1e-06	0.00178	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	3.09e-06	0.00178	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.05e-06	0.00175	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—HRAS—urinary bladder cancer	3.01e-06	0.00173	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	2.98e-06	0.00171	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	2.94e-06	0.00169	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—IGFBP3—urinary bladder cancer	2.93e-06	0.00168	CbGpPWpGaD
Galantamine—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	2.91e-06	0.00167	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	2.91e-06	0.00167	CbGpPWpGaD
Galantamine—BCHE—Phospholipid metabolism—PTEN—urinary bladder cancer	2.87e-06	0.00165	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP4B1—urinary bladder cancer	2.86e-06	0.00164	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	2.85e-06	0.00163	CbGpPWpGaD
Galantamine—BCHE—Metabolism—UGT2B7—urinary bladder cancer	2.83e-06	0.00162	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	2.83e-06	0.00162	CbGpPWpGaD
Galantamine—ACHE—Metabolism—SLC19A1—urinary bladder cancer	2.7e-06	0.00155	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	2.69e-06	0.00154	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	2.66e-06	0.00152	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PRSS3—urinary bladder cancer	2.63e-06	0.00151	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—IGFBP3—urinary bladder cancer	2.61e-06	0.0015	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.57e-06	0.00148	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP4B1—urinary bladder cancer	2.55e-06	0.00146	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	2.53e-06	0.00145	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.49e-06	0.00143	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.48e-06	0.00142	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	2.45e-06	0.00141	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.42e-06	0.00139	CbGpPWpGaD
Galantamine—BCHE—Metabolism—SLC19A1—urinary bladder cancer	2.41e-06	0.00138	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—HRAS—urinary bladder cancer	2.4e-06	0.00137	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	2.38e-06	0.00137	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—HRAS—urinary bladder cancer	2.37e-06	0.00136	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.37e-06	0.00136	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PRSS3—urinary bladder cancer	2.35e-06	0.00135	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	2.31e-06	0.00133	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.3e-06	0.00132	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	2.25e-06	0.00129	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.22e-06	0.00127	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	2.19e-06	0.00126	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—HRAS—urinary bladder cancer	2.17e-06	0.00124	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.11e-06	0.00121	CbGpPWpGaD
Galantamine—ACHE—Metabolism—TYMP—urinary bladder cancer	2.1e-06	0.00121	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.06e-06	0.00118	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—HRAS—urinary bladder cancer	2.06e-06	0.00118	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—HRAS—urinary bladder cancer	2.04e-06	0.00117	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.02e-06	0.00116	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.02e-06	0.00116	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—HRAS—urinary bladder cancer	1.93e-06	0.00111	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.92e-06	0.0011	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.91e-06	0.00109	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NAT2—urinary bladder cancer	1.9e-06	0.00109	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.88e-06	0.00108	CbGpPWpGaD
Galantamine—BCHE—Metabolism—TYMP—urinary bladder cancer	1.88e-06	0.00108	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.8e-06	0.00103	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NAT2—urinary bladder cancer	1.7e-06	0.000973	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.69e-06	0.000972	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—HRAS—urinary bladder cancer	1.68e-06	0.000962	CbGpPWpGaD
Galantamine—ACHE—Metabolism—RRM2—urinary bladder cancer	1.64e-06	0.000942	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	1.6e-06	0.000919	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.58e-06	0.000907	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.56e-06	0.000896	CbGpPWpGaD
Galantamine—ACHE—Metabolism—HPGDS—urinary bladder cancer	1.52e-06	0.000872	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ENO2—urinary bladder cancer	1.52e-06	0.000872	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.51e-06	0.000867	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	1.5e-06	0.000861	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSTT1—urinary bladder cancer	1.47e-06	0.000846	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	1.47e-06	0.000845	CbGpPWpGaD
Galantamine—BCHE—Metabolism—RRM2—urinary bladder cancer	1.46e-06	0.00084	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.45e-06	0.000833	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.45e-06	0.000833	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	1.42e-06	0.000817	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	1.42e-06	0.000817	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.39e-06	0.000799	CbGpPWpGaD
Galantamine—BCHE—Metabolism—HPGDS—urinary bladder cancer	1.36e-06	0.000778	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ENO2—urinary bladder cancer	1.36e-06	0.000778	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.35e-06	0.000773	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSTT1—urinary bladder cancer	1.32e-06	0.000755	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	1.3e-06	0.000747	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.3e-06	0.000743	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—IGF1—urinary bladder cancer	1.24e-06	0.000711	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NQO1—urinary bladder cancer	1.23e-06	0.000703	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—HRAS—urinary bladder cancer	1.2e-06	0.000687	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.19e-06	0.000682	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	1.17e-06	0.000672	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	1.11e-06	0.000635	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—IGF1—urinary bladder cancer	1.11e-06	0.000634	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NQO1—urinary bladder cancer	1.09e-06	0.000627	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	1.08e-06	0.000619	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—HRAS—urinary bladder cancer	1.07e-06	0.000612	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.06e-06	0.000608	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.04e-06	0.000595	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSTP1—urinary bladder cancer	1.02e-06	0.000586	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—CXCL8—urinary bladder cancer	9.96e-07	0.000572	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.89e-07	0.000567	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	9.82e-07	0.000563	CbGpPWpGaD
Galantamine—ACHE—Metabolism—TYMS—urinary bladder cancer	9.5e-07	0.000545	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NCOR1—urinary bladder cancer	9.39e-07	0.000539	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSTM1—urinary bladder cancer	9.39e-07	0.000539	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	9.31e-07	0.000534	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	9.31e-07	0.000534	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.25e-07	0.000531	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSTP1—urinary bladder cancer	9.12e-07	0.000523	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GPX1—urinary bladder cancer	8.99e-07	0.000516	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—CXCL8—urinary bladder cancer	8.89e-07	0.00051	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ERCC2—urinary bladder cancer	8.83e-07	0.000507	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.82e-07	0.000506	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	8.63e-07	0.000495	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	8.51e-07	0.000488	CbGpPWpGaD
Galantamine—BCHE—Metabolism—TYMS—urinary bladder cancer	8.48e-07	0.000486	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSTM1—urinary bladder cancer	8.38e-07	0.000481	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NCOR1—urinary bladder cancer	8.38e-07	0.000481	CbGpPWpGaD
Galantamine—ACHE—Metabolism—MTHFR—urinary bladder cancer	8.3e-07	0.000476	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GPX1—urinary bladder cancer	8.02e-07	0.00046	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ERCC2—urinary bladder cancer	7.88e-07	0.000452	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	7.8e-07	0.000447	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	7.66e-07	0.00044	CbGpPWpGaD
Galantamine—BCHE—Metabolism—MTHFR—urinary bladder cancer	7.41e-07	0.000425	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	7.24e-07	0.000415	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	7.05e-07	0.000405	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	6.73e-07	0.000386	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PPARG—urinary bladder cancer	6.73e-07	0.000386	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CREBBP—urinary bladder cancer	6.47e-07	0.000371	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	6.24e-07	0.000358	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	6.24e-07	0.000358	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	6.05e-07	0.000347	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PPARG—urinary bladder cancer	6e-07	0.000344	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CREBBP—urinary bladder cancer	5.77e-07	0.000331	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	5.64e-07	0.000323	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PTGS2—urinary bladder cancer	5.3e-07	0.000304	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	5.1e-07	0.000293	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	5.03e-07	0.000288	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PTGS2—urinary bladder cancer	4.72e-07	0.000271	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PTEN—urinary bladder cancer	4.62e-07	0.000265	CbGpPWpGaD
Galantamine—ACHE—Metabolism—EP300—urinary bladder cancer	4.4e-07	0.000253	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	4.4e-07	0.000253	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	4.19e-07	0.00024	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PTEN—urinary bladder cancer	4.12e-07	0.000236	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.08e-07	0.000234	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.08e-07	0.000234	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.95e-07	0.000227	CbGpPWpGaD
Galantamine—BCHE—Metabolism—EP300—urinary bladder cancer	3.93e-07	0.000225	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	3.9e-07	0.000224	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	3.85e-07	0.000221	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	3.85e-07	0.000221	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	3.69e-07	0.000212	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	3.62e-07	0.000208	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	3.4e-07	0.000195	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.29e-07	0.000189	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.76e-07	0.000158	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.74e-07	0.000157	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.65e-07	0.000152	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.55e-07	0.000146	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.52e-07	0.000144	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.52e-07	0.000144	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.41e-07	0.000138	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.37e-07	0.000136	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.23e-07	0.000128	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.17e-07	0.000125	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.89e-07	0.000109	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.81e-07	0.000104	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.81e-07	0.000104	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.73e-07	9.95e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.42e-07	8.14e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.24e-07	7.1e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.18e-07	6.77e-05	CbGpPWpGaD
